Adipose tissue dysregulation has a major role in various human diseases. The peroxisome proliferator-activated receptor-c (PPARc) is a key regulator of adipocyte differentiation and function, as well as a target of insulin-sensitizing drugs. The Hsp90 chaperone stabilizes a diverse set of signaling 'client' proteins, thereby regulates various biological processes. Here we report a novel role for Hsp90 in controlling PPARc stability and cellular differentiation. Specifically, we show that the Hsp90 inhibitors geldanamycin and novobiocin efficiently impede the differentiation of murine 3T3-L1 preadipocytes. Geldanamycin at higher concentrations also inhibits the survival of both developing and mature adipocytes, respectively. Further, Hsp90 inhibition disrupts an Hsp90-PPARc complex, leads to the destabilization and proteasomal degradation of PPARc, and inhibits the expression of PPARc target genes, identifying PPARc as an Hsp90 client. A similar destabilization of PPARc and a halt of adipogenesis also occur in response to protein denaturing stresses caused by a single transient heat-shock or proteasome inhibition. Recovery from stress restores PPARc stability and adipocyte differentiation. Thus, our findings reveal Hsp90 as a critical stress-responsive regulator of adipocyte biology and offer a potential therapeutic target in obesity and the metabolic syndrome.
White adipose tissue is an active metabolic endocrine organ that imparts on whole-body homeostasis. Adipose tissue expansion (obesity) and a consequent dysregulation have a prominent role in various systemic diseases including the metabolic syndrome.
1,2 The nuclear transcription factor, peroxisome proliferator-activated receptor g (PPARg), emerged as a prime regulator of adipocyte biology. 3, 4 PPARg belongs to the RXR-heterodimeric group 1 of the nuclear receptor superfamily (NR1C3). Of its two major isoforms, PPARg1 is expressed in a variety of tissues, including the liver, skeletal muscle, macrophages, adipose tissue and bone. PPARg2 possesses a 30-amino-acid extension at its extreme N-terminus, and exclusively occurs in adipogenic cells. 4 General and adipose-specific deletion of PPARg in mice [5] [6] [7] and dominant-negative PPARg mutations in humans 8 lead to lipodystrophy and severe insulin resistance. PPARg activation by the antidiabetic thiazolidinediones as well as by adipocytetargeted transgene expression of PPARg2 improves insulin sensitivity, adipokine and inflammatory profiles. 9 Similarly, human studies showed that a Pro12Ala variant of PPARg2 confers protection from weight gain and diabetes mellitus. 10 Consistently, PPARg 2 as well as its Pro12Ala variant contribute to longevity in mice. 11, 12 The above examples show a profound impact of optimal adipose PPARg function on systemic physiology and healthspan.
In response to adipogenic signals, parallel activation of the CCAAT/enhancer-binding proteins (C/EBP) b and d induces a mitotic clonal expansion (i.e., several rounds of postconfluent mitosis) of preadipocytes, as well as a marked transcriptional induction of PPARg and C/EBPa. 4, 13 Although PPARg works in concert with C/EBPa, PPARg is necessary and sufficient for adipogenesis. PPARg-deficient embryonic stem cells are unable to differentiate into adipocytes, 14, 15 whereas ectopic expression of PPARg in mouse embryonic fibroblasts drives adipogenesis in the absence of C/EBPa. 16 Once activated by natural lipid derivatives, PPARg heterodimerizes with RXR and regulates the transcription of hundreds of genes leading to terminal differentiation. 17 Besides, PPARg is also indispensable for both function and survival of mature adipocytes. 18, 19 An intricate regulation of PPARg function also involves post-translational mechanisms including sumoylation and ubiquitin-dependent proteasomal degradation, [20] [21] [22] but is not fully understood.
Heat-shock protein 90 (Hsp90) is an evolutionarily conserved molecular chaperone essential for the folding and activity of several hundred thermodynamically unstable 'client' proteins, mainly kinases and nuclear receptors involved in cellular signaling, proliferation and cell survival. [23] [24] [25] (For a complete list of clients, see: www.picard.ch/downloads/ Hsp90interactors.pdf.) Besides a uniform Hsp90 dependence of NR3 steroid receptors, NR1 members exhibit a variable degree of reliance on Hsp90 from full dependence (aryl-hydrocarbon receptor) through absolute independence (thyroid receptor). 23, 26, 27 An earlier study found that all PPARs associated with bacterially expressed Hsp90 in vitro. 28 However, contrary to the predominantly supportive Hsp90-client interactions, Hsp90 was not required for PPARa stability, repressed PPARa and PPARb reporter activity, whereas did not significantly affect a PPARg-dependent reporter. This example illustrates the individuality of Hsp90 interactions even among highly similar PPAR relatives. Moreover, the role of Hsp90 in PPARg function remained unexplored.
Hsp90 occurs in two homologous and functionally redundant isoforms: in contrast to the more constitutive and ubiquitous Hsp90b, Hsp90a exhibits a more stress-inducible and rather tissue-specific expression. 24 The chaperone cycle of Hsp90 is coordinated by ATP-binding and hydrolysis and involves a dynamic association of co-chaperones. 23 The N-terminal nucleotide antagonist geldanamycin (GA), 29 and other Hsp90 inhibitors disrupt the ATPase/chaperone cycle and destabilize diverse clients, offering a single-hit-multitarget type anticancer treatment. 30 Hsp90 also regulates the heat-shock response by releasing the heat-shock transcription factor HSF1 upon binding to denatured proteins. 31 However, the impact of proteostasis on Hsp90-client interactions remained elusive. Despite the increased awareness of the role of the heat-shock response in metabolic stress and obesity, 32 the involvement of Hsp90 in these conditions is, yet, similarly unclear. In this study, we investigate how Hsp90 and proteotoxic stress regulate adipogenesis and delineate the potential molecular mechanisms involved.
Results
Hsp90 inhibition impedes differentiation and survival of 3T3-L1 preadipocytes. To investigate how Hsp90 modulates adipogenesis, mouse 3T3-L1 preadipocytes, a widely used experimental model was employed. 33 In response to hormonal stimulation, 3T3-L1 cells terminally differentiate into mature adipocytes in 2 weeks ( Figure 1a ) and accumulate triglycerides in lipid droplets, readily stained by Oil Red O (Figure 1b) . A transient treatment of preadipocytes at the terminal differentiation phase by the Hsp90-specific N-terminal inhibitor geldanamycin (GA) efficiently suppressed adipogenesis in a concentration-dependent manner (Figures 1b and c) . A similar inhibitory effect was obtained using the C-terminal Hsp90 inhibitor, novobiocin 34 (Supplementary Figure S1) . Thus, various forms of Hsp90 inhibition compromised the terminal differentiation of 3T3-L1 cells.
Hsp90 inhibition might prevent differentiation through inducing cell death. However, we observed a large number of viable undifferentiated preadipocytes in response to either Hsp90 inhibitor (see the attached, unstained, elongated cells in Figure 1b and Supplementary Figure S1a) . Therefore, we quantitatively analyzed both differentiation and viability from parallel GA-treated samples on day 14. Consistent with Hsp90's role in cell survival, GA induced extensive cell death, especially at higher concentrations. However, GA progressively compromised differentiation exceeding an over 80% inhibition at 56 nM without a significant effect on viability. Moreover, kinetic analysis revealed a 10-fold lower IC50 value of GA on differentiation compared with that on survival (16.38 versus 163.6 nM), which was virtually unaffected by normalization to viability (Figure 1c and Supplementary  Table S1 ). These results suggest that the differentiationpromoting effect of Hsp90 is a consequence of other than its pro-survival mechanism(s).
Hsp90 inhibition depletes PPARc protein levels. Next, we investigated potential molecular mechanisms behind the GA-induced inhibition of adipogenesis. PPARg is a master transcriptional regulator of adipocyte differentiation, acting in the terminal differentiation phase. 4, 17 Indeed, we observed a robust induction of PPARg1 protein during adipocyte differentiation, starting from day 2 with a shift in favor of the adiposespecific PPARg2 later ( Supplementary Figures S2a and b) . Importantly, an overnight GA treatment entirely depleted both Table S1 ). Besides the abundant, modestly inducible Hsp90b, Hsp90a was only detected in response to strong proteotoxic insults and remained at the detection limit in GA-treated 3T3-L1 cells (Figure 2a ; Supplementary Figures  S2a-d) . These findings do not exclude a PPARg-Hsp90a interaction, but suggest that both PPARg isoforms are predominantly chaperoned by Hsp90b in 3T3-L1 cells. GA under these conditions partially decreased the protein level of Akt, a known Hsp90 client, 35 which has a key role in insulin/IGF1-signaling acting downstream of phosphatidylinositol-3-kinase, a potent activator of adipogenesis 9, 36 ( Figures 2a and b) . Accordingly, overnight treatment of 3T3-L1 cells with pharmacologic doses of the specific PI3K inhibitor LY294002 partially compromised adipogenesis ( Supplementary Figures S3a and b) . Hence, inhibition of the PI3K/Akt pathway by GA may contribute to the inhibition of 3T3-L1 differentiation. GA did not affect the level of the PPARg cooperator, C/EBPa p42, which is consistent with an intact signaling/transcriptional function leading to terminal differentiation (Figure 2a ). GA treatment also decreased PPARg protein levels in HepG2 human hepatocytes (Supplementary Figure S4) . Moreover, novobiocin depleted PPARg in 3T3-L1 cells (Figure 2c ). Thus, Hsp90 stabilizes PPARg protein in mammalian cells.
Inhibition of the Hsp90-PPARc interaction triggers destabilization and proteasomal degradation of PPARc. To address whether PPARg and Hsp90 physically interact, we immunoprecipitated endogenous PPARg protein from 3T3-L1 adipocytes. Hsp90 was detected in a physical complex with PPARg, which was disrupted by a 2-h GA treatment (Figure 3a) . PPARg is subject to proteasomemediated turnover. 20, 21 Prompted by these findings, we asked whether PPARg might misfold and undergo proteasomal degradation in response to Hsp90 inhibition. Indeed, GA caused the complete disappearance of PPARg from both the detergent soluble supernatant and insoluble pellet fractions of 3T3-L1 cell lysates (Figure 3b) . A parallel treatment by the proteasome inhibitor MG132 induced the accumulation of both PPARg and Akt in the detergent-insoluble pellet, demonstrating a destabilization-induced aggregation of PPARg.
The timescale of GA treatment indicated a fast kinetics of PPARg depletion (Figure 3c ). Use of the translation inhibitor, cycloheximide revealed a rapid turnover of PPARg within 4 h (Figure 3c ), in agreement with the robust expression, and proteasomal degradation of activated PPARg. 21 Altogether, these results demonstrate that an association with Hsp90 is Hsp90 function is required for PPARc transcriptional output and for survival of mature adipocytes. Next, we investigated how Hsp90 inhibition affects PPARg-driven downstream events. GA treatment prevented the induction of PPARg-dependent target mRNAs important for autonomous (GLUT4, aP2) and for systemic (adiponectin) functions of adipocytes (Figure 4a ). Moreover, GA treatment inhibited the expression of PPARg2 mRNA itself, suppressing a positive auto-regulatory loop. The respective PPARg target mRNAs exhibited almost identical GA-concentration dependence and IC50 values, which were close to that of PPARg protein depletion (Supplementary Table S1 ). Hence, Hsp90 function is necessary for the transcriptional response of PPARg, which creates and maintains the functional characteristics of mature adipocytes. 19 Assessing the protein levels of PPARg and the master adipokine adiponectin revealed their parallel decline in GAtreated mature adipocytes (Supplementary Figure S5) . Hsp90 is generally a pro-survival protein, 30 and PPARg has been reported to ensure the survival of mature adipocytes in mice. 18 Therefore, we investigated the impact of Hsp90 inhibition on the viability of differentiated 3T3-L1 cells. Significant cytotoxic effect was observed after a 48-h GA treatment, when a large 4b and c ). An B2.5-fold longer treatment duration on day 12 produced a similar IC50 value to the 20-h GA treatment on day 3 (170.2 versus 163.6 nM). Therefore, Hsp90 also ensures the survival of mature adipocytes.
Proteotoxic stress halts adipogenesis via abrogating the Hsp90-PPARc complex. Recent evidence confirmed that Hsp90 binds thermodynamically unstable proteins. 25 As an increasing amount of misfolded proteins may overload Hsp90 capacity, we investigated how proteotoxic stress interferes with PPARg stability and adipogenesis. Strikingly, a transient moderate heat shock at 431C employed on day 3 in differentiating 3T3-L1 cells induced a quantitative depletion of PPARg, which was in contrast to the unchanged level of C/EBPa p42 (Figures 5a and b) . As an underlying mechanism, the entire amount of PPARg was rapidly misfolded and sedimented in the detergent-insoluble pellet, even if proteasome function was not pharmacologically inhibited (Figure 5c ). This phenomenon was consistent with an increased load of the ubiquitin-proteasome system by heat-denatured substrates. In agreement with this, we were unable to immunoprecipitate PPARg from the soluble fraction of heat-shocked lysates. However, Hsp90 largely preserved its solubility, indicating a loss of interaction with PPARg. Under these conditions, B50% of Akt became insoluble (Figure 5c ). The differential solubility of PPARg and Akt paralleled their different sensitivity to Hsp90 inhibition (see Figures 2a and b) , and suggests a stronger dependency of PPARg on Hsp90 compared with Akt, and therefore its stronger aggregation in response to heat shock.
The transient folding defect of PPARg in response to a moderate heat shock significantly inhibited PPARg-dependent transcription, including a failure to increase its own mRNA expression by day 14 of adipocyte differentiation ( Figure 5d ). As a consequence, heat-shock treatment led to the cessation of adipocyte differentiation, while up to 120 min it did not largely interfere with cell survival (Figures 5e and f) .
In physiological conditions, B30% of newly synthesized proteins are mistranslated, misfolded and degraded by the proteasome. 37 Therefore, we increased misfolded protein load by partial proteasome inhibition as an independent proteotoxic challenge. Indeed, a 20-h treatment with the proteasome inhibitor MG132 resulted in the destabilization of PPARg (but not that of C/EBPa p42), inhibition of PPARg target gene expression, as well as an impaired adipogenesis, similar to the effects observed after heat-shock and GA treatments (Supplementary Figures S6a-d) .
Recovery from stress allows the continuation of adipogenic program by the restoration of PPARc function. The above observations demonstrated that different forms of global proteotoxic stress exert similar effects to pharmacological Hsp90 inhibition and abrogate all PPARg folding, function and adipogenesis. To investigate whether adipocyte differentiation is reversibly restored upon attenuation of stress, after various doses of GA or heat-shock treatments on day 3, 3T3-L1 preadipocytes were re-exposed to the stimuli inducing differentiation on day 5 (Figure 6a ). Cells were able to restore differentiation at a progressively decreasing level with increasing doses of GA and heat- Figures S7a-d) . To assess the relationship between cell differentiation and PPARg stability, we selected two conditions (112 nM GA and 2-h heat shock). Both treatments are characterized by maximal inhibition of differentiation and PPARg, along with maximal preservation of viability to circumvent the influence of residual PPARg activity and extensive cell death, respectively, on differentiation in response to the repeated stimulus. Re-exposure of cells to the differentiation medium led to a successful differentiation of the majority of the heatshocked, but not GA-treated, cell population (Figure 6b ), in line with the complete restoration of stabilized PPARg protein levels after recovery from a transient heat shock, but not after GA treatment, respectively (Figure 6c ). The slight appearance of PPARg protein in GA-treated cells after the re-differentiation stimulus is consistent with the intracellular accumulation of, and sustained inhibition of Hsp90 by, GA (Figures 4a and 5d) . 30 Neither intervention changed total Hsp90 protein level significantly (Figure 6c ). These data suggest that recovery from stress allows the restoration of PPARg stability and adipogenic function (Figure 6d ).
Discussion
Our study revealed a critical requirement of Hsp90 for the differentiation and survival of 3T3-L1 adipocytes and provided an underlying molecular mechanism by the identification of the master regulator PPARg as an Hsp90 client. Both specific Hsp90 inhibition and general proteotoxic stresses (heat-shock or proteasome inhibition) equally disrupted the Hsp90-PPARg complex, destabilized PPARg and halted adipogenesis. However, upon relief from stress, the differentiation program was continued by the restoration of PPARg function.
The absolute requirement of Hsp90 for PPARg stability and activity ( Figures 2-4) is analogous with that of NR3 steroid receptors and many kinases 23 and indicates that PPARg is a strong Hsp90 client, which appears unique among PPAR isoforms. 28 Systemic analysis of Hsp90-kinase interactions 25 and our data suggest that PPARg harbors a level of conformational instability that makes it dependent on Hsp90. The discordant interaction of Hsp90 with PPARs 28 despite their B80% sequence similarity may provide a tool to shed further light on the structural attributes that drive Hsp90/client recognition of nuclear receptors.
PPARg is necessary and sufficient for adipogenesis [14] [15] [16] and is required for adipocyte survival in mice. 18 Our findings that GA treatment phenocopied PPARg loss-of-function ( Figures 1-4 and Supplementary Table S1) identifies the downregulation of PPARg as an important downstream consequence of Hsp90 inhibition in adipocytes. Being an Hsp90 client creates an opportunity for regulation by a plethora of Hsp90-associated proteins. Indeed, the elegant evidence of such regulation, that a dephosphorylation of PPARg at Ser-112 by the Hsp90 co-chaperone protein phosphatase 5 is indispensable for adipogenesis, has recently been published. 38 In addition to PPARg, several pathways involving Hsp90 clients (including the insulindependent PI3K pathway, the mineralocorticoid receptor, as well as calcineurin and b-catenin in Wnt signaling) may contribute to Hsp90's effect on adipocyte differentiation and survival. 36, 39, 40 As an important example, we also observed a GA-induced depletion of Akt. In turn, adipose PPARg2 transgene induces Akt activation in mice, and insulin signaling promotes PPARg activity. 3, 9 Thus, GA may inhibit activatory crosstalks between insulin and PPARg signaling. We suggest that the strong impact of Hsp90 inhibition beyond destabilizing individual clients also lies in affecting their interactions.
We observed prominent similarities of proteotoxic stresses ( Figure 5 and Supplementary Figure S6) to pharmacologic Hsp90 inhibition. The stress-induced destabilization of the Hsp90 clients PPARg and Akt suggests an increased load of Hsp90 by the expansion of the conformationally unstable pool of its clients resulting in its decreased support to PPARg function and adipogenic signaling. Further experiments ( Figure 6) showed that, upon cessation of stress, cells have the ability to restore the Hsp90-dependent support of adipogenesis. Pioneering studies from Susan Lindquist's group extended by others demonstrated that stresses burdening the Hsp90 buffer give rise to adaptive evolutionary changes. 24, [41] [42] [43] However, what may be the benefit of the Hsp90-client interaction in the same generation? Our findings demonstrate that the interactions of Hsp90 with PPARg and Akt modulate cellular function and phenotype in a stressresponsive manner. We propose that Hsp90 provides a steady-state sensor, through which preadipocytes are able to immediately tune PPARg activity, signaling and biological function with changing environmental conditions. Hsp90 is able to sense the ATP/ADP ratio, and ATP depletion in vivo has been reported to disrupt some Hsp90-client complexes. 44, 45 Therefore, we hypothesize that PPARg chaperoning might also be responsive to fluctuations in energy supply. Such a regulation may especially be useful in times of stress when fat mobilization fuels organismal adaptation.
An analogous stress-induced mechanism operates the heat-shock response through the dissociation of HSF1. 31 Similarly, reduction in Hsp90 level in HSF1/3-deficient cells mediates growth arrest upon heat shock by the destabilization of Cdc2. 46 We anticipate that the dynamic interactions with a diverse clientele may render Hsp90 a versatile stressresponsive modulator of complex biological responses.
In light of the increasing awareness that an optimal number of healthy adipocytes along with a robust PPARg function are key to systemic health and lifespan, 1,2,9,11 our results may have broad therapeutic relevance. Accumulating evidence on a significant adipocyte turnover highlights adipogenesis as a therapeutic target in obesity. 47, 48 Importantly, we found a much more potent inhibition of PPARg by GA in adipocytes versus hepatoma cells (Figure 2 and Supplementary Figure S4 which is reminiscent to the increased addiction of cancer cell clients to Hsp90. 30 Similarly, GA inhibited preadipocyte differentiation, preadipocyte survival and mature adipocyte survival, respectively, to progressively decreasing extent (Figures 1c and 4b) . Hence, adipose Hsp90 inhibition might potently limit obesity by preventing adipocyte renewal and weight gain. However, considering the pivotal role of Hsp90 in various physiological processes in diverse tissues, further in vivo studies are needed to assess the feasibility of Hsp90 inhibition and the potential requirement of its adipose-specific targeting as a therapeutic strategy.
On the other hand, the vulnerability of the Hsp90-PPARg interaction (Figures 2, 5 and 6 ) might limit PPARg function and the response to thiazolidinediones in chronic distress, such as the metabolic syndrome. 32 Chaperone induction by different approaches, including a modest pharmacologic Hsp90 inhibition, has been widely shown to combat various age-related diseases. 24, 49 Accordingly, these findings suggest that upregulation of the Hsp90 chaperone complex could strengthen adipocyte proteostasis and boost optimal PPARg/client and adipose function. Such a possibility may gain support by the findings that chaperone induction either by systemic hyperthermia or by geranylgeranylacetone and BGP-15 drugs promote weight loss and/or improve insulin resistance in rodents and humans. [50] [51] [52] [53] [54] The involvement of adipose Hsp90 and PPARg in these approaches, as well as the impact of adipose Hsp90/chaperone upregulation on systemic health, are exciting opportunities of further studies.
Our results on the GA-induced depletion of PPARg in human hepatoma cells (Supplementary Figure S4) suggest that Hsp90 also stabilizes PPARg in extra-adipose tissues. In addition to the TGFb receptor, 55 PPARg represents another anti-proliferative, differentiation-promoting Hsp90-client. Considering a dual, but primarily protective role of PPARg in cancer, 56 it may be of interest to determine the efficacy of Hsp90 inhibition on tumor regression depending on the PPARg background. Extra-adipose PPARg in the liver, macrophages and brain modulates metabolism, inflammation, atherosclerosis and neuropathophysiology. 3 Therefore, the demonstration of a critical regulation of PPARg by Hsp90 may open additional avenues of chaperone-related therapies in the treatment of various age-related diseases.
Materials and Methods
Materials. Reagents for cell culture were from Gibco-Invitrogen (Carlsbad, CA, USA). Antibodies against PPARg were from Abcam (Cambridge, UK) and from Cell Signaling Technology (Danvers, MA, USA). Anti-Akt, anti-C/EBPa and antiadiponectin antibodies were from Cell Signaling Technology, and anti-b-actin was from Sigma (St. Louis, MO, USA). Anti-Hsp90, Hsp90a and Hsp90b antibodies were from Institute of Immunology Ltd. (Tokyo, Japan). Geldanamycin and novobiocin were from Sigma . The PI3K inhibitor LY294002 and the proteasome inhibitor MG132 were from Cell Signaling Technology and Calbiochem (San Diego, CA, USA), respectively. Complete protease inhibitor tablets were from Roche (Mannheim, Germany). Protein assay, electrophoresis and blotting reagents were from Bio-Rad (Hercules, CA, USA). The ECL kit was from Perkin-Elmer (Wellesley, MA, USA). All other reagents were from Sigma or Fluka (Buchs, Switzerland).
Cell culture. 3T3-L1 mouse fibroblasts and HepG2 human hepatoma cells were obtained from the ATCC. Both cell types were maintained in Dulbecco's modified Eagle medium (with 4.5 mg/ml glucose), supplemented with 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 100 mg/ml streptomycin and 100 IU/ml penicillin at isobaric oxygen in 5% CO 2 at 37 1C. 3T3-L1 and HepG2 cells were cultured in the presence of 10% bovine or 10% fetal bovine serum, respectively.
Adipocyte differentiation and treatments. 3T3-L1 cells were cultured to confluence. Differentiation was induced 2 days post-confluence (designated as day 0) by 1 mM dexamethasone, 0.5 mM isobutylmethylxanthine and 1 mM ciglitizone. After 48 h, cells were incubated with 1 mM ciglitizone for 48 h. Subsequently, cells were maintained in DMEM supplemented with 10% fetal bovine serum till the end of the experiments. Cells were treated with various concentrations of geldanamycin, the PI3K inhibitor LY294002, heat-shock and/or the proteasome inhibitor MG132 as specified in the figure legends.
Oil Red O staining and viability. Cellular fat accumulation was monitored by Oil Red O staining on day 14 either visualized by microscopy or quantified by photometry. Oil Red O stock solution was prepared at 0.5% in isopropanol. Cells were cultured either on coverslips or in six-well plates, washed twice with PBS and fixed with 10% formalin in PBS for at least 1 h. After two washes in distilled water and 10 min incubation in 60% isopropanol, cells were stained for 10 min in Oil Red O solution freshly diluted into distilled water at a ratio of 3 : 2, followed by five washes in distilled water. Coverslips were mounted using Vectashield (Vector Laboratories, Burlingame, CA, USA) visualized and imaged by a Nikon Eclipse E400 microscope/camera. Plates were observed using an Alpha XD2-2T inverted microscope and photographed by an Alpha DMC-510 USB camera. For photometry cells were allowed to dry, and Oil Red O was eluted by isopropanol for 10 min. Optical density was measured at 500 nm by a Thermo Varioskan Flash photometer (Thermo Scientific, Wiesbaden, Germany) using isopropanol as blank. In order to directly compare cell survival with differentiation, parallel samples from the same experiments were assayed on the same day both for triglyceride accumulation by Oil Red O incorporation and for viability by trypan blue exclusion.
Cell lysis, purification of aggregates and western blotting. After treatments, cells were lysed on ice with WB lysis buffer (50 mM Tris, 300 mM NaCl, 1 mM MgCl 2 , 0.5 mM EDTA, 0.1 mM EGTA, 20% glycerol, 1% NP40, 0.5 mM DTT, 2 Â Complete, pH 7.6) for 20 min at 41C, vigorously vortexed, and centrifuged at 13 000 r.p.m. for 10 min in a microcentrifuge. Protein concentration of the supernatants was determined by Bradford method, and equal amounts of proteins were subjected to SDS-PAGE. The aggregation of PPARg was assessed as previously described. 57 Briefly, detergent-insoluble pellets, containing aggregated proteins, were solubilized in urea buffer (2% SDS, 6 M urea, 30 mM Tris, pH 7.6). Equal volumes of protein extracts from each fraction were resolved by SDS-PAGE. Western blotting was performed by transfer to nitrocellulose membrane and by blocking in 5% (w/v) skim milk powder. Blots were probed with the appropriate primary antibodies overnight at 4 1C and incubated with peroxidase-conjugated secondary antibodies for an hour at room temperature and developed using ECL detection. The protein levels were determined by densitometric analysis of the western blots using the Image J (NIH, Bethesda, MD, USA) and normalized to the corresponding b-actin level.
mRNA expression analysis. mRNA was prepared and was reverse transcribed using the GeneJET RNA Purification Kit and the RevertAid TM cDNA Synthesis Kit, respectively (Fermentas, Vilnius, Lithuania). Sequences of primer sets for mouse PPARg2, adiponectin, GLUT4, aP2 and 28S rRNA were described elsewhere. 58 Quantitative PCR was performed in an ABI 7300 System by using Maxima SYBR Green/ROX qPCR Master Mix (Fermentas) according to the manufacturer's instructions. Relative amounts of mRNA were determined using the Comparative CT Method for quantification and were normalized to 28S rRNA levels.
Immunoprecipitation. 5 Â 10 6 cells were treated by 0.25 mg/ml geldanamycin or DMSO for 2 h. Then, cells were washed three times and scraped in icecold PBS. Lysis was performed in IP lysis buffer (50 mM Tris, 2 mM EDTA, 100 mM NaCl, 1 mM Na 3 VO 4 , 1% NP40, 2x Complete). PPARg was immunoprecipitated by a monoclonal anti-PPARg antibody. Pellets were washed five times with lysis buffer and analyzed by SDS-PAGE and immunoblotting with anti-Hsp90 and anti-PPARg antibodies.
Statistical analysis. Data were compared by two-tailed unpaired t-test. Variables were expressed as mean ± standard deviation (s.d). Statistical significance was indicated as follows: *Po0.05, **Po0.01, ***Po0.001.
